切换导航
关闭
  • 菜单
  • Setting

Signaling Pathways - FLT3 - 5-HT1 Receptor - Prostaglandin EP receptors - Bcr-Abl

36件产品中的 1-10

页面
每页
清除全部
  1. Dasatinib Monohydrate
    B5954 Dasatinib Monohydrate
    中文名: 达沙替尼一水合物
    Target: PDGFR|c-Kit|Bcr-Abl|Src
    Summary: ABL\SRC\KIT\PDGFR以及其它酪氨酸激酶抑制剂
      ≥25.3 mg/mL
      insoluble in H2O
  2. Dovitinib (TKI258) Lactate
    B5953 Dovitinib (TKI258) Lactate
    Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR
    Summary: 酪氨酸激酶抑制剂(TKI)
      ≥10.62 mg/mL
      ≥168.2 mg/mL
  3. Pexidartinib (PLX3397)
    B5854 Pexidartinib (PLX3397)
     3 Citation
    中文名: 培西达替尼
    Target: FLT3|c-Kit|CSF1R
    Summary: CSF-1R抑制剂
      ≥20.9 mg/mL
      insoluble in H2O
  4. Radotinib(IY-5511)
    B5846 Radotinib(IY-5511)
    中文名: 雷多替尼
    Target: PDGFR|Bcr-Abl
    Summary: Bcr-Abl酪氨酸激酶抑制剂
      ≥13.73 mg/mL
      insoluble in H2O
  5. AZD2932
    B5835 AZD2932
    Target: FLT3|VEGFR|PDGFR|c-Kit
    Summary: VEGFR-2\PDGFRβ\Flt-3和c-Kit的抑制剂
      Soluble in DMSO
  6. Altiratinib
    B5832 Altiratinib
     1 Citation
    Target: FLT3|VEGFR|Trk Receptors|c-MET|Tie-2
    Summary: c-MET/TIE-2/VEGFR抑制剂
      ≥21.55 mg/mL
      insoluble in H2O
  7. UNC2025
    B8016 UNC2025
     1 Citation
    Target: MER|FLT3
    Summary: 口服生物可利用的双重MER/FLT3抑制剂
      ≥23.85 mg/mL
      ≥6.09 mg/mL
  8. G-749
    A8889 G-749
    Target: Aurora Kinases|FLT3|c-RET
    Summary: FLT3抑制剂
      ≥26.05 mg/mL
      insoluble in H2O
  9. SCH 23390 hydrochloride
    B6506 SCH 23390 hydrochloride
    Target: dopamine receptor|5-HT1 Receptor|5-HT2 Receptor
    Summary: 多巴胺受体拮抗剂
      Soluble to 100 mM in sterile water and to 50 mM in ethanol
  10. Methylergometrine maleate
    B6347 Methylergometrine maleate
    中文名: 马来酸甲麦角新碱
    Target: 5-HT1 Receptor|5-HT2 Receptor
    Summary: 5-HT1/5-HT2受体拮抗剂
      Soluble to 25 mM in H2O

36件产品中的 1-10

页面
每页